Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...290291292293294295296297298299300...10661067»
  • ||||||||||  dexamethasone / Generic mfg., cytarabine / Generic mfg.
    Journal, IO biomarker:  Dexamethasone Sensitizes Acute Monocytic Leukemia Cells to Ara-C by Upregulating FKBP51. (Pubmed Central) -  Jul 23, 2022   
    Furthermore, SAFit2, a specific FKBP51 inhibitor, increased U937 cell viability and cytarabine resistance as well as AKT phosphorylation. In conclusion, FKBP51 decelerates proliferation and improves the cytarabine sensitivity of AML-M5 cells by inhibiting AKT pathways, and dexamethasone in combination with Ara-C improves the chemosensitivity of AML-M5.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Hypercortisolemic Cushing's patients possess a distinct class of hematopoietic progenitor cells leading to erythrocytosis. (Pubmed Central) -  Jul 22, 2022   
    Although human cultures stimulated with dexamethasone suggest that the glucocorticoid receptor (GR) activates stress erythropoiesis, the effects of GR activation on erythropoiesis in vivo remains poorly understood...Collectively, these results indicate that chronic exposure to excess glucocorticoids in vivo leads to erythrocytosis by generating erythroid progenitor cells with a constitutively active GR. Although remission rescues the erythrocytosis and the phenotype of the circulating CD34+ cells, a memory of other prior changes is maintained in remission.
  • ||||||||||  dexamethasone injection / Generic mfg.
    Journal:  Treatment of Meniere's disease by Multi-session Dexamethasone Injections. (Pubmed Central) -  Jul 22, 2022   
    Although remission rescues the erythrocytosis and the phenotype of the circulating CD34+ cells, a memory of other prior changes is maintained in remission. multi-session Intra-tympanic dexamethasone injection is superior to the single injection in control of vertigo in patients with definite MD.
  • ||||||||||  Sarclisa (isatuximab-irfc) / Sanofi
    Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Final Overall Survival Analysis (Petree Hall C) -  Jul 21, 2022 - Abstract #IMW2022IMW_112;    
    P3
    Introduction: The anti-CD38 monoclonal antibody isatuximab (Isa) combined with pomalidomide and dexamethasone (Pd) is approved in several countries for patients (pts) with relapsed and refractory multiple myeloma (RRMM) who have received ≥2 prior treatments (tx), including lenalidomide and a proteasome inhibitor, based on the primary analysis of the Phase 3 ICARIA-MM study (NCT02990338). This final OS analysis demonstrates a clinically meaningful benefit with a 6.9-month improvement in median OS and significantly improved time to next tx and PFS2, with a manageable safety profile, which further supports Isa-Pd as a standard-of-care therapy for pts with RRMM.
  • ||||||||||  bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
    Value-based care: engaging myeloma patients in the selection of patient reported outcome measures (515A) -  Jul 21, 2022 - Abstract #IMW2022IMW_36;    
    No single PROM fully captured the wide range of concerns prioritised by participants. We will use the set of patient-informed PROMs in a future study to assess impact of bortezomib, lenalidomide and dexamethasone on the HRQoL of the newly diagnosed, transplant ineligible patients.
  • ||||||||||  Riarify (beclometasone/formoterol/glycopyrrolate) / Chiesi
    Trial completion, Enrollment change, Trial completion date, HEOR, Adherence:  TriOptimize: Non-interventional Study Related to Fixed LAMA/LABA/ICS Triple Therapy (clinicaltrials.gov) -  Jul 21, 2022   
    P=N/A,  N=94, Completed, 
    Here, we present a comprehensive dissection of alterations in the composition of the BM immune microenvironment, demonstrate that PB mirrors the composition of the BM immune compartment, and provide evidence of post-therapy immune normalization, which could have prognostic implications. Active, not recruiting --> Completed | N=200 --> 94 | Trial completion date: Jun 2023 --> Jun 2022
  • ||||||||||  Kenalog-10 (triamcinolone acetonide) / BMS
    Trial primary completion date:  Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis (clinicaltrials.gov) -  Jul 21, 2022   
    P4,  N=10, Recruiting, 
    Active, not recruiting --> Completed | N=200 --> 94 | Trial completion date: Jun 2023 --> Jun 2022 Trial primary completion date: Jun 2022 --> Dec 2022
  • ||||||||||  dexamethasone injection / Generic mfg.
    Trial completion date, Trial primary completion date:  Dexamethasone in Total Knee Arthroplasty (clinicaltrials.gov) -  Jul 21, 2022   
    P4,  N=429, Recruiting, 
    Trial completion date: Feb 2025 --> Jul 2026 Trial completion date: Sep 2022 --> May 2023 | Trial primary completion date: Jun 2022 --> Dec 2022
  • ||||||||||  methylprednisolone acetate / Generic mfg.
    Trial completion:  BMAC: BMA vs Cortisone for Glenohumeral Osteoarthritis (clinicaltrials.gov) -  Jul 20, 2022   
    P2/3,  N=34, Completed, 
    Recruiting --> Active, not recruiting Active, not recruiting --> Completed
  • ||||||||||  mometasone furoate / Generic mfg.
    THE VOICE REGISTRY: A VITILIGO DATABASE – OUR FIRST YEAR () -  Jul 20, 2022 - Abstract #GVF2022GVF_5;    
    The most commonly prescribed treatments are tacrolimus 0.1% ointment (46%), followed by narrowband UVB (nb-UVB) phototherapy (36%) and topical mometasone furoate 0.1% ointment (33%)...CONCLUSION We wish to present the data that we have been able to collect thus far through the registry, in particular focussing on the effectiveness of nb-UVB phototherapy demonstrated within our patient cohort. We hope by demonstrating the usefulness of our database to encourage other centres across the country to participate in the study and enter their vitiligo cohort into the database enabling us to create a national database that enhances research within vitiligo in the U.K. Future projects being planned includes deep phenotyping and whole excime sequencing.
  • ||||||||||  Ocaliva (obeticholic acid) / Intercept
    HEPATOBILIARY DISORDERS IN INFLAMMATORY BOWEL DISEASE: WHAT COULD BE THE OPTIMAL MANAGEMENT WHEN PRIMARY BILIARY CHOLANGITIS PRECEDES THE ONSET OF CROHN ILEITIS? A SIXTY-SIX YEARS OLD FEMALE PATIENT CASE REPORT (Science Lounge) -  Jul 20, 2022 - Abstract #UEGW2022UEGW_2730;    
    We hope by demonstrating the usefulness of our database to encourage other centres across the country to participate in the study and enter their vitiligo cohort into the database enabling us to create a national database that enhances research within vitiligo in the U.K. Future projects being planned includes deep phenotyping and whole excime sequencing. Clinical Case Summary: Hepatobiliary disorders’ association with inflammatory bowel diseases (IBDs) has been widely proven.However, the concomitance of Primary Biliary Cholangitis (PBC) and Crohn’s disease (CD) is anecdotical, usually described in male young patients with a diagnosis of IBD preceding the onset of PBC.We report the case of a 66-year-old female patient with pre-existent PBC at the moment of the CD-ileitis identification.She was admitted for recurrent abdominal colic pain and irrepressible chronic diarrhea; her family history didn’t reveal any inflammatory or neoplastic gut disorders; PBC and Hashimoto’s thyroiditis were the highlighted comorbidities.PBC was diagnosed 5 years before,treated for two years with the administration of 15 mg/Kg/die ursodeoxycholic acid (UDCA) which,because of the severe diarrhea, was then stopped.After an inconclusive chronic diarrhea diagnostic work-up (table), further examinations were performed, including colonoscopy and MRI-enterography, both assessing a picture suitable for CD.The combination of the clinical, endoscopic, and radiologic findings realized the final diagnosis of Crohn’s Ileitis causing ileal substenosis in a patient with PBC.Given the UDCA intolerance,an oral monotherapy treatment using obeticholic acid 5 mg/die was prescribed.Considering the concomitant diagnosis of ileal-CD and the potential benefits described as off-label therapy on PBC patients,budesonide 9 mg/die per os was also administered.One month after discharge, an improvement was observed both in cholestasis indexes and gastrointestinal symptoms.According to our experience, all IBD patients should be constantly screened for hepatobiliary manifestations, to provide an early setting of a tailored therapeutic path.Table >
  • ||||||||||  hydrocortisone / Generic mfg.
    ULCERATED POLYPOIDAL LESION IN RECTUM: NOT ALWAYS A MALIGNANCY (Science Lounge) -  Jul 20, 2022 - Abstract #UEGW2022UEGW_2708;    
    The child was managed with laxatives, pelvic floor exercise and hydrocortisone enema for 3 months...Mitsunaga et al reported an association of polypoid CCP lesion with adenocarcinoma.2 Therefore, careful histological examination of all CCP is advisable to exclude associated malignancy. This condition is rewarding to treat.
  • ||||||||||  Cosentyx (secukinumab) / Novartis
    SECUKINUMAB INDUCED ULCERATIVE COLITIS IN A PATIENT WITH PSORIASIS AND SUBSEQUENT MANAGEMENT (Science Lounge) -  Jul 20, 2022 - Abstract #UEGW2022UEGW_2694;    
    The patient was treated with oral plus rectal mesalazine and a reducing course of oral prednisolone, without significant improvement...In conjunction with the dermatologist, the decision was made to stop secukinumab and treat her with infliximab without a washout period...Additionally, co-trimoxazole was initiated for Pneumocystis pneumonia prophylaxis...In January 2020, azathioprine was added to the treatment and she reported significant improvement with bowels opening 4-5 times per day and resolution of blood/mucus in the stool. Faecal calprotectin levels dropped to 21 and psoriasis was reported to be well controlled.
  • ||||||||||  Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
    UNUSUAL DIAGNOSIS IN A PATIENT WITH DYSPEPSIA (Science Lounge) -  Jul 20, 2022 - Abstract #UEGW2022UEGW_2631;    
    Clinical Case Summary: This is a case of a 42-year-old man with seronegative spondyloarthropathy and primary biliary cholangitis under golimumab and ursodeoxycholic acid...The patient started treatment with budesonide with an improvement of symptoms...It is classified as either secondary (most commonly associated with celiac disease or Helicobacter pylori gastritis) or idiopathic. Lymphocytic gastritis is of clinical importance since its recognition should prompt further clinical evaluation for other disorders.
  • ||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron
    DUPILUMAB FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS: A MULTICENTER REAL-LIFE EXPERIENCE (Poster Stage 4) -  Jul 20, 2022 - Abstract #UEGW2022UEGW_1549;    
    Five patients received Dupilumab and 12 were treated with StF (9 with viscous budesonide and 3 with oral fluticasone).  Our study confirms that Dupilumab may represent a valid therapeutic option in refractory EoE, improving clinical, endoscopic and especially histological activity of the disease.